Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20098
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPorter, Tenielle-
dc.contributor.authorBurnham, Samantha C-
dc.contributor.authorSavage, Greg-
dc.contributor.authorLim, Yen Ying-
dc.contributor.authorMaruff, Paul-
dc.contributor.authorMilicic, Lidija-
dc.contributor.authorPeretti, Madeline-
dc.contributor.authorAmes, David-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorSalvado, Olivier-
dc.contributor.authorTaddei, Kevin-
dc.contributor.authorGroth, David-
dc.contributor.authorVerdile, Giuseppe-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorLaws, Simon M-
dc.date2018-12-19-
dc.date.accessioned2019-01-18T04:19:41Z-
dc.date.available2019-01-18T04:19:41Z-
dc.date.issued2018-12-19-
dc.identifier.citationFrontiers in aging neuroscience 2018; 10: 423en
dc.identifier.issn1663-4365-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/20098-
dc.description.abstractStudies of Alzheimer's disease risk-weighted polygenic risk scores (PRSs) for cognitive performance have reported inconsistent associations. This inconsistency is particularly evident when PRSs are assessed independent of APOE genotype. As such, the development and assessment of phenotype-specific weightings to derive PRSs for cognitive decline in preclinical AD is warranted. To this end a episodic memory-weighted PRS (emPRS) was derived and assessed against decline in cognitive performance in 226 healthy cognitively normal older adults with high brain Aβ-amyloid burden participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. The effect size for decline in a verbal episodic memory was determined individually for 27 genetic variants in a reference sample (n = 151). These were then summed to generate a emPRS either including APOE (emPRSc̅APOE) or excluding APOE (emPRSs̅APOE ). Resultant emPRS were then evaluated, in a test sample (n = 75), against decline in global cognition, verbal episodic memory and a pre-Alzheimer's cognitive composite (AIBL-PACC) over 7.5 years. The mean (SD) age of the 226 participants was 72.2 (6.6) years and 116 (51.3%) were female. Reference and test samples did not differ significantly demographically. Whilst no association of emPRSs were observed with baseline cognition, the emPRSc̅ APOE was associated with longitudinal global cognition (-0.237, P = 0.0002), verbal episodic memory (-0.259, P = 0.00003) and the AIBL-PACC (-0.381, P = 0.02). The emPRSs̅ APOE was also associated with global cognition (-0.169, P = 0.021) and verbal episodic memory (-0.208, P = 0.004). Stratification by APOE ε4 revealed that the association between the emPRS and verbal episodic memory was limited to carriage of no ε4 or one ε4 allele. This was also observed for global cognition. The emPRS and rates of decline in AIBL-PACC were associated in those carrying one ε4 allele. Overall, the described novel emPRS has utility for the prediction of decline in cognition in preclinical AD. This study provides evidence to support the further use and evaluation of phenotype weightings in PRS development.en
dc.language.isoeng-
dc.subjectAlzheimer’s diseaseen
dc.subjectAβ-amyloiden
dc.subjectcognitive declineen
dc.subjectepisodic memoryen
dc.subjectpolygenic risk scoreen
dc.titleA Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease.en
dc.typeJournal Articleen
dc.identifier.journaltitleFrontiers in aging neuroscienceen
dc.identifier.affiliationARC Centre of Excellence in Cognition and its Disorders, Department of Psychology, Macquarie University, North Ryde, NSW, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationCogState Ltd., Melbourne, Victoria, Australiaen
dc.identifier.affiliationCollaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australiaen
dc.identifier.affiliationCooperative Research Centre (CRC) for Mental Health, Carlton, Victoria, Australiaen
dc.identifier.affiliationSchool of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australiaen
dc.identifier.affiliationCSIRO Health and Biosecurity, Parkville, Victoria, Australiaen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, Victoria, Australiaen
dc.identifier.doi10.3389/fnagi.2018.00423en
dc.type.contentTexten
dc.identifier.pubmedid30620773-
dc.type.austinJournal Article-
local.name.researcherMasters, Colin L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.